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IL = interleukin; TGF = transforming growth factor; Treg = regulatory T cells.
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Introduction
The mammalian immune system has evolved a number of
potent mechanisms to protect the individual from the wide
range of pathogens that can infect it, but these effector
mechanisms can often be damaging to the host, as well as
to the pathogens that evoke them. For example, the tissue
necrosis that accompanies the chronic inflammation of
tuberculosis is caused not by the bacillus but by the
immune response to it. Similarly, acute hypersensitivity
reactions to otherwise innocuous sensitising agents may
be unnecessary but life threatening, because of their
effects on the respiratory system or cardiovascular
system. Finally, there are a number of autoimmune dis-
eases in which the immune system mounts a specific
response against the tissues of the host.
Given these ample illustrations that the mammalian immune
response is potentially lethal to the host, one may ask why
are not all individuals equally susceptible to the types of
diseases described? Currently, no comprehensive answer
to this question can be given. Nonetheless, research in
immune homeostasis in the past 10 to 15 years has
demonstrated the existence of a T-cell-mediated regulatory
system that appears to have evolved specifically to prevent
autoimmunity and that may play an equally vital role in mod-
erating the immune response to foreign antigens.
Evidence for regulatory T cells in the control
of autoimmunity
It has been a widely held view that thymocytes with recep-
tors for self antigens expressed in the thymus are purged
from the developing T-cell repertoire by the process of
clonal deletion. It was further accepted that tolerance to
self antigens expressed exclusively in extrathymic sites
was a consequence of either peripheral deletion of auto-
reactive T cells or the induction of nonresponsiveness
(anergy) in these cells. However, these mechanisms were
not compatible with the observation that rodents made rel-
atively lymphopenic by a variety of experimental proce-
dures developed a wide range of autoimmune diseases:
gastritis, diabetes, thyroiditis, oophoritis, and hepatitis.
Several methods of generating the lymphopenia resulted
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in organ-specific autoimmunity: thymectomy in the first
3 days of life, adult thymectomy plus 137Cs g irradiation,
partial restoration of T-cell numbers in genetically T-cell-
deficient recipients, by the transfer of a limited number of
T cells from normal congenic donors.
The key observation in all of these systems was that the
development of disease could be prevented if the lympho-
penic animals were given a particular subset of CD4+
peripheral T cells or CD4+ CD8– thymocytes from normal
donors (reviewed [1–3]).
These experiments established three points:
1. Autoreactive T cells are to be found in normal, healthy
animals that show no tendency to develop autoimmune
disease.
2. These autoreactive T cells can be controlled by a
defined subset of CD4+ T cells, now termed regulatory
T cells, or Treg. Most of these cells express CD25, the
IL-2R a chain.
3. Treg are present in the thymus and in the periphery.
The role of Treg in the control of immune
responses to foreign antigens
Rodents made relatively T-cell-deficient in CD25+ CD4+
T cells can develop severe inflammatory infiltrates in their
lungs and an inflammation of the colon resembling ulcera-
tive colitis [4,5]. Restoration of the deficiency in Treg in
these rodents prevents these inflammatory diseases. It
seems likely that, in both lungs and colon, the inflamma-
tion is induced by a dysregulated response to foreign
antigens; germ-free mice do not get colitis [6]. While the
specificity of the Treg that prevents these inflammatory
diseases is not known, it is notable that the thymus is a
potent source of these protective cells. These results may
be interpreted in at least two ways. One interpretation is
that Treg from the thymus provide a peripheral microenvi-
ronment for the induction of Treg that are specific for the
foreign antigens causing the inflammation. An alternative
interpretation is that the recognition of self antigens by
Treg in the periphery moderates inflammatory responses
by modifying the functions of antigen-presenting cells
(see below) or by producing anti-inflammatory cytokines.
Whichever mode of action proves to be the true one, it
appears that Treg have not evolved solely to prevent
autoimmunity, but also to control immune responses to
foreign antigens. Indeed, a case might be made for main-
taining that the latter role is their primary one and that
subliminal autoimmunity in normal individuals serves the
essential function of promoting the survival of Treg in the
periphery.
The tissue distribution and characterisation
of Treg
In the periphery, Treg are present in lymph node, spleen,
thoracic duct lymph, and blood. In both rats and mice,
they have the phenotype of memory cells, as judged by
the low-molecular-mass isoform of CD45 that they
express. The majority, but not all, are CD25+ [2,3,7]. In
view of the memory phenotype of these peripheral cells, it
was surprising to find that the thymus is a rich source of
Treg [8]. However, these  cells also express CD25 and
are found among the mature CD4+ subset of thymocytes
that expresses L-selectin; they are not peripheral cells
that have returned to the thymus from the periphery.
These findings showed that, in addition to its well recog-
nised role in the positive and negative selection of thymo-
cytes, the thymus has a third function, that of generating
Treg [9].
The mode of action of Treg and their antigen
specificity
Treg isolated from the thymus, or from peripheral lymphoid
tissue, can inhibit in vitro T-cell activation induced either
by specific antigen or by the T-cell mitogens concanavalin
A (Con A) and phytohaemagglutinin (PHA). However, they
cannot prevent activation induced by the combination of
calcium ionophore and phorbol esters nor by cross-linking
of the T-cell receptor by plate-bound anti-CD3 monoclonal
antibody. Further, the inhibition by Treg of mitogen-
induced activation requires that these cells make cognate
interactions with the T cells that they are inhibiting and
with the antigen-presenting cells that are essential for
T-cell mitogens to function. In contrast, it is not possible to
abrogate this inhibition by adding anti-cytokine antibodies
to the T-cell cultures [10,11]. These results suggest that
Treg mediate their inhibitory effects by interfering directly
with the stimulatory function of dendritic cells and there is
experimental evidence that this is so [12–14]. The interac-
tion of Treg with dendritic cells results in the downregula-
tion of expression of the costimulatory molecules CD80
and CD86, which play an essential role in the activation of
naïve T cells [14]. Further, Treg that prevent organ-
specific autoimmunity and inflammatory bowel disease in
mice constituitively express CTLA-4, which is a ligand for
both CD80 and CD86 [15–17]. It is not yet known
whether the interaction between CTLA-4 on Treg and its
ligands on dendritic cells is directly responsible for the
downregulation of ligand expression. However, antibodies
to CTLA-4 in vitro and in vivo abrogate the inhibitory
action of Treg [15–17].
These results contrast with those from in vivo tests of the
function of Treg, where there is clear evidence for a role
for anti-inflammatory cytokines. Neutralising antibodies, to
IL-4 and transforming growth factor (TGF)-b, prevent Treg
from protecting rats from lymphopenia-induced autoim-
mune thyroiditis [18], and in mice, IL-10 and TGF-b have
been shown to play an essential role in the prevention of
inflammatory bowel disease by Treg [19,20]. Taken
together, the results found in vitro and in vivo indicate that
Treg have at least two modes of action.c
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Antigen-specificity of Treg
Peripheral CD4+ memory T cells from young adult rats that
have had their thyroid glands ablated by exposure in utero
to 131I are not able to prevent autoimmune thyroiditis on
transfer into syngeneic recipients made lymphopenic by
adult thymectomy and 137Cs g irradiation. As described
above, peripheral CD4+ memory T cells from euthyroid
donors are able to do so. This deficiency of protective
capacity of Treg from athyroid animals appears specific for
thyroid autoimmunity; Treg from these rats are perfectly
able to protect rats from lymphopenia-induced diabetes.
Significantly, thymocytes from athyroid rats function as
effectively as those from euthyroid donors in preventing
thyroiditis in lymphopenic recipients. It appears that the
absence of a thyroid gland does not impair the intrathymic
generation of Treg that can prevent autoimmune thyroidi-
tis, but it does cause a failure of these cells to survive in
the periphery [21].
It is difficult to account for these results other than by
assuming that Treg specifically recognise the autoantigen
that they are protecting.
Conclusion
Regulatory T cells have been demonstrated in mouse, rat,
and man [Stephens L and coworkers, paper submitted],
but much remains to be learnt about their homeostasis
and their site and mode of action. It seems likely that a rel-
ative deficiency of Treg is at least one cause of diseases
that arise through inappropriate immune responses to self
and foreign antigens. There is also a theoretical possibility,
yet to be fully explored, that they inhibit protective immune
reponses to malignant cells. They are, therefore, of clinical
interest for several reasons and they are currently being
studied intensively.
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